ArticleBMC infectious diseases2026
Impact of serum ferritin on the efficacy of hydrocortisone in septic patients: a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis is associated with high morbidity and mortality. Whether serum ferritin can guide hydrocortisone therapy in sepsis remains uncertain.
methodsA retrospective cohort was constructed from the Medical Information Mart for Intensive Care IV(MIMIC-IV). Septic patients with ferritin measured within 1 day of onset were included. Serum ferritin levels were compared between 28-day survivors and non-survivors. A receiver operating characteristic (ROC) curve was used to identify the optimal cut-off value of serum ferritin for predicting 28-day mortality, stratifying patients into high- and low-ferritin groups. Variables associated with 28-day mortality were selected by least absolute shrinkage and selection operator (LASSO) regression. Inverse probability of treatment weighting (IPTW) was applied to balance baseline differences between groups. The effect of hydrocortisone on 28-day mortality was then analyzed in the weighted cohort.
resultsAmong 718 septic patients, 169 died within 28 days. Median serum ferritin was 476ng/ml (Inter Quartile Range [IQR]:197–1190) in survivors versus 818ng/ml (IQR:284–2200) in non-survivors (P < 0.001). The ROC-derived cut-off value was 526ng/ml. Higher ferritin was associated with increased 28-day mortality (Odds Ratio [OR] = 1.97, 95%CI:1.54–2.52; P < 0.001). Hydrocortisone was not associated with 28-day mortality (OR = 1.14, 95%CI:0.90–1.45; P = 0.276). No interaction between serum ferritin and hydrocortisone was observed (P-interaction = 0.882). In both high- and low-ferritin subgroups, hydrocortisone remained unrelated to 28-day mortality (OR = 1.24, 95%CI:0.90–1.72 and OR = 1.07, 95%CI 0.74–1.56, respectively).
conclusionsElevated serum ferritin is associated with higher 28-day mortality in septic patients. Ferritin status does not modify the efficacy of hydrocortisone in sepsis. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.